695 related articles for article (PubMed ID: 32796930)
1. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.
Tabrizi SJ; Flower MD; Ross CA; Wild EJ
Nat Rev Neurol; 2020 Oct; 16(10):529-546. PubMed ID: 32796930
[TBL] [Abstract][Full Text] [Related]
2. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
[TBL] [Abstract][Full Text] [Related]
4. A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes.
Ciosi M; Maxwell A; Cumming SA; Hensman Moss DJ; Alshammari AM; Flower MD; Durr A; Leavitt BR; Roos RAC; ; ; Holmans P; Jones L; Langbehn DR; Kwak S; Tabrizi SJ; Monckton DG
EBioMedicine; 2019 Oct; 48():568-580. PubMed ID: 31607598
[TBL] [Abstract][Full Text] [Related]
5. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
6. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
Tabrizi SJ; Ghosh R; Leavitt BR
Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
[TBL] [Abstract][Full Text] [Related]
7. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
[TBL] [Abstract][Full Text] [Related]
8. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
9. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying neurodegeneration in Huntington disease: applications to novel disease-modifying therapies.
Ross CA; Kronenbuerger M; Duan W; Margolis RL
Handb Clin Neurol; 2017; 144():15-28. PubMed ID: 28947113
[TBL] [Abstract][Full Text] [Related]
13. Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity.
Lemarié FL; Caron NS; Sanders SS; Schmidt ME; Nguyen YTN; Ko S; Xu X; Pouladi MA; Martin DDO; Hayden MR
Neurobiol Dis; 2021 Oct; 158():105479. PubMed ID: 34390831
[TBL] [Abstract][Full Text] [Related]
14. Promotion of somatic CAG repeat expansion by Fan1 knock-out in Huntington's disease knock-in mice is blocked by Mlh1 knock-out.
Loupe JM; Pinto RM; Kim KH; Gillis T; Mysore JS; Andrew MA; Kovalenko M; Murtha R; Seong I; Gusella JF; Kwak S; Howland D; Lee R; Lee JM; Wheeler VC; MacDonald ME
Hum Mol Genet; 2020 Nov; 29(18):3044-3053. PubMed ID: 32876667
[TBL] [Abstract][Full Text] [Related]
15. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
16. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
17. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
18. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
Fodale V; Boggio R; Daldin M; Cariulo C; Spiezia MC; Byrne LM; Leavitt BR; Wild EJ; Macdonald D; Weiss A; Bresciani A
J Huntingtons Dis; 2017; 6(4):349-361. PubMed ID: 29125493
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategies for Huntington's disease.
Estevez-Fraga C; Flower MD; Tabrizi SJ
Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
[TBL] [Abstract][Full Text] [Related]
20. Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic Approach.
Mariani LL; Tesson C; Charles P; Cazeneuve C; Hahn V; Youssov K; Freeman L; Grabli D; Roze E; Noël S; Peuvion JN; Bachoud-Levi AC; Brice A; Stevanin G; Durr A
JAMA Neurol; 2016 Sep; 73(9):1105-14. PubMed ID: 27400454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
